<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZECUITY- sumatriptan succinate patch, extended release, electrically controlled </strong><br>NuPathe Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ZECUITY<span class="Sup">®</span> safely and effectively.  See full prescribing information for ZECUITY.<br>ZECUITY<span class="Sup">® </span><span class="Bold">(sumatriptan iontophoretic transdermal system)</span><br>Initial U.S. Approval: 1992</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ZECUITY is a serotonin (5HT) 1b/1d receptor agonist (triptan) indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults (<a href="#ID_2b5b672e-e0a5-445e-856c-24d0774adf25">1</a>) </p>
<p class="Highlighta"><span class="Underline">Limitations of Use:</span> </p>
<dl>
<dt>•</dt>
<dd>Use only after a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established (<a href="#ID_2b5b672e-e0a5-445e-856c-24d0774adf25">1</a>)</dd>
<dt>•</dt>
<dd>Not indicated for the prevention of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks (<a href="#ID_2b5b672e-e0a5-445e-856c-24d0774adf25">1</a>)</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>For transdermal use only (<a href="#ID_dccc3bcf-654a-43d5-a4b2-da37d120e369">2</a>)</dd>
<dt>•</dt>
<dd>Acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>: Single ZECUITY transdermal system (TDS) applied to dry, intact, non-irritated skin of upper arm or thigh (<a href="#ID_dccc3bcf-654a-43d5-a4b2-da37d120e369">2</a>)</dd>
<dt>•</dt>
<dd>No more than two ZECUITY should be used in any 24 hour period; second TDS should be used no sooner than 2 hours after activation of first TDS (<a href="#ID_dccc3bcf-654a-43d5-a4b2-da37d120e369">2</a>)</dd>
<dt>•</dt>
<dd>ZECUITY TDS should not be applied to a previous application site until that site remains <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> free for at least 3 days (<a href="#ID_dccc3bcf-654a-43d5-a4b2-da37d120e369">2</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Iontophoretic transdermal system:  Delivers 6.5 mg of sumatriptan over 4 hours (<a href="#ID_d87e4ad0-1a59-464b-800f-290142cfe3e7">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>History of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) or <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span> (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd>Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd>History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack, or hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd>Ischemic bowel disease (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd>Recent (within 24 hours) use of another 5-HT<span class="Sub">1</span> agonist (e.g., another triptan) or of an ergotamine-containing medication (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd>Use of monoamine oxidase-A inhibitor in past 2 weeks (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to sumatriptan or components of ZECUITY (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span> to ZECUITY (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Magnetic Resonance Imaging procedure (MRI):</span> ZECUITY contains metal parts and must be removed before an MRI procedure (<a href="#ID_77a9791c-31df-4121-8623-1840c3516710">5.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span> (ACD): </span>Discontinue ZECUITY if ACD is suspected (<a href="#ID_aa49bd42-caf1-4480-97e8-4565044fa70a">5.2</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>/<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> and Prinzmetal’s angina: </span>Perform cardiac evaluation in patients with multiple cardiovascular risk factors (<a href="#ID_e2b3728e-fd27-4a77-a2f7-18fde92682ac">5.3</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>: </span>Discontinue ZECUITY if occurs (<a href="#ID_4b25deb8-1d4e-4263-b2c8-59664056e7ec">5.4</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Chest/throat/neck/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, tightness, pressure, or heaviness:</span> Generally not <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>; evaluate high risk patients for CAD (<a href="#ID_3b651027-8f4b-495a-bd26-db1704acd1ab">5.5</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>:</span> Discontinue ZECUITY if occurs (<a href="#ID_7b1a6b7b-1fd2-4da5-9379-a201fe0215d6">5.6</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Gastrointestinal <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> events, peripheral vasospastic reactions:</span> Discontinue ZECUITY if occurs (<a href="#ID_6e949668-c82d-48ca-b984-e4f0f34e2aaa">5.7</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>:</span> Detoxification may be necessary (<a href="#ID_82e22dcc-4358-4b6a-ba99-6258c4f2236f">5.8</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥ 5%) were <span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">application site pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, warmth, and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (<a href="#ID_2f4a8f8c-da04-485c-86b1-1f5e0d3fbb88">6.1</a>) </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or <span class="Italics"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a></span> </p>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: Based on animal data, may cause fetal harm (<a href="#ID_f6e39cff-472e-4add-8f1d-18811e4b8c94">8.1</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE </a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS </a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Risk of Injury During Magnetic Resonance Imaging (MRI) Procedure </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic Contact Dermatitis</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal’s Angina </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Chest, Throat, Neck and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Cerebrovascular Events </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Increase in Blood Pressure </a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> </a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Electrically-active Implantable or Body-worn Medical Devices </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS </a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Ergot-Containing Drugs </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Monoamine Oxidase-A Inhibitors </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Other 5-HT<span class="Sub">1 </span>Agonists </a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers </a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use </a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE </a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION </a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action </a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics </a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY </a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology </a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES </a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Acute Migraine</span> Attack – Placebo Controlled Efficacy Study </a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<h2><a href="#section-19.1" class="toc">Zecuity® (sumatriptan iontophoretic transdermal system) 6.5 mg/4 hours, 4s Carton Text </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_2b5b672e-e0a5-445e-856c-24d0774adf25"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE </h1>
<p class="First">ZECUITY is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults. </p>
<p><span class="Underline">Limitations of Use</span>:</p>
<dl>
<dt>•</dt>
<dd>Use only if a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established.</dd>
<dt>•</dt>
<dd>If a patient has no response to the first <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack treated with ZECUITY reconsider the diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> before ZECUITY is administered to treat any subsequent attacks.</dd>
<dt>•</dt>
<dd>ZECUITY is not intended for the prevention of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks.  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_dccc3bcf-654a-43d5-a4b2-da37d120e369"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<p class="First">ZECUITY is for transdermal use only and is designed for patient self-administration to the upper arm or thigh (see <a href="#id-1951062375">Figure 1</a>). ZECUITY should not be applied to other areas of the body.  ZECUITY should not be cut.  </p>
<p>The maximum recommended single dose is one ZECUITY iontophoretic transdermal system (TDS). No more than two ZECUITY TDS should be used in any 24 hour period, and the second ZECUITY TDS should be applied no sooner than 2 hours after activation of the first ZECUITY TDS.  There is no evidence of benefit for the use of a second ZECUITY TDS to treat <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> recurrence or incomplete <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> relief during a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. </p>
<p>ZECUITY should be applied to dry intact, non-irritated skin on the upper arm or thigh on a site that is relatively hair free and is without <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>, tattoos, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span>, or other skin conditions (i.e., generalized <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span> or disease including <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, melanoma, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>). ZECUITY should not be applied to a previous application site until the site remains <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> free for at least 3 days.</p>
<div class="Figure">
<a name="id-1951062375"></a><img alt="Figure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-01.jpg"><p class="MultiMediaCaption">Figure 1: Applied Transdermal System</p>
</div>
<p>ZECUITY delivers 6.5 mg of sumatriptan over 4 hours. Once applied, the activation button must be pushed, and the red light emitting diode (LED) will turn on. ZECUITY TDS must be applied and activated within 15 minutes of initiation of assembly. When dosing is completed, the system stops operating and the activation light turns off, signaling that the system can be removed. Once dosing is completed, the system cannot be reactivated. If the light turns off before 4 hours, dosing has stopped and ZECUITY can be removed. If <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> relief is incomplete, a second ZECUITY TDS can be applied to a different site. <span class="Italics">[see Patient Counseling Information (<a href="#ID_454aae2a-29f0-49a7-b7d7-63b264951e17">17</a>)].</span></p>
<p>The ZECUITY TDS should remain in place for 4 hours or until the red LED light goes off. The iontophoretic device can be secured with medical tape if needed. </p>
<p>The safety of using more than 4 ZECUITY in one month has not been established. </p>
<p>ZECUITY is for single use only. After use, the TDS should be folded so the adhesive side sticks to itself and safely discarded away from children and pets. ZECUITY contains lithium-manganese dioxide batteries; it should be disposed in accordance with state and local regulations.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_d87e4ad0-1a59-464b-800f-290142cfe3e7"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">Iontophoretic transdermal system: 6.5 mg over 4 hours.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS </h1>
<p class="First">ZECUITY is contraindicated in patients with:</p>
<dl>
<dt>·</dt>
<dd>Ischemic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>) or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, including Prinzmetal’s angina <span class="Italics">[see Warnings and Precautions (<a href="#ID_e2b3728e-fd27-4a77-a2f7-18fde92682ac">5.3</a>)]</span>. </dd>
<dt>•</dt>
<dd>Wolff-Parkinson-White syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders <span class="Italics">[see Warnings and Precautions (<a href="#ID_4b25deb8-1d4e-4263-b2c8-59664056e7ec">5.4</a>)]. </span>
</dd>
<dt>•</dt>
<dd>History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack (TIA), or history of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> because these patients are at a higher risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <span class="Italics">[s</span>ee <span class="Italics">Warnings and Precautions (<a href="#ID_7b1a6b7b-1fd2-4da5-9379-a201fe0215d6">5.6</a>)]</span>.  </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_6e949668-c82d-48ca-b984-e4f0f34e2aaa">5.7</a>)]</span>. </dd>
<dt>•</dt>
<dd>Ischemic bowel disease <span class="Italics">[see Warnings and Precautions (<a href="#ID_6e949668-c82d-48ca-b984-e4f0f34e2aaa">5.7</a>)]</span>. </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_3083bf10-ba96-4e4d-ab4a-31badaa4f6c0">5.10</a>)]</span>. </dd>
<dt>•</dt>
<dd>Recent (i.e., within 24 hours) use of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine<span class="Sub">1</span> (5-HT<span class="Sub">1</span>) agonist <span class="Italics">[see Drug Interactions (<a href="#ID_dd93d7f9-5ebe-4b41-81d0-6d2b3ae30e4d">7.1</a>,<a href="#ID_1b3c04bf-e4b3-4689-939e-1a1a3572b918">7.3</a>)]</span>. </dd>
<dt>•</dt>
<dd>Concurrent administration of an MAO-A inhibitor or recent (within 2 weeks) use of a MAO-A inhibitor <span class="Italics">[see Drug Interactions (<a href="#ID_b61ea82b-1a2f-4a67-87fb-9a07434ccf0b">7.2</a>) and Clinical Pharmacology (<a href="#ID_ed5b332d-61e9-4d8d-8656-3d3d2c7249eb">12.3</a>)]. </span>
</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sumatriptan or components of ZECUITY <span class="Italics">[see Warnings and Precautions (<a href="#ID_aa49bd42-caf1-4480-97e8-4565044fa70a">5.2</a>,<a href="#ID_a12d6238-32d7-4aed-8f65-c4c4c66d5040">5.11</a>)]</span>. </dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Clinical Pharmacology (<a href="#ID_ed5b332d-61e9-4d8d-8656-3d3d2c7249eb">12.3</a>)]</span>.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span> to ZECUITY <span class="Italics">[see Warnings and Precautions (<a href="#ID_aa49bd42-caf1-4480-97e8-4565044fa70a">5.2</a>)]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_cfbf33fd-e3f1-4bf4-bf40-f74a4bbbf7fb"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_77a9791c-31df-4121-8623-1840c3516710"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Risk of Injury During Magnetic Resonance Imaging (MRI) Procedure </h2>
<p class="First">ZECUITY contains metal parts and must be removed before an MRI procedure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aa49bd42-caf1-4480-97e8-4565044fa70a"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic Contact Dermatitis</span> </h2>
<p class="First">Use of ZECUITY may lead to <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> (ACD).  In two long-term open-label studies where patients were allowed to treat multiple <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks for up to 1 year, the overall adverse event rate of ACD was 4%.  ZECUITY should be discontinued if ACD is suspected. <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> is commonly seen with use of ZECUITY and is not by itself an indication of sensitization. Following sensitization with ZECUITY, erythematous plaque and/or erythemato-vesicular or erythemato-<span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruptions</span> may develop. Clinical course is characterized by crescendo phenomenon of worsening <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and appearance over time with slower resolution to normal of affected skin areas. </p>
<p>Patients sensitized from use of ZECUITY, as evidenced by development of ACD, may develop systemic sensitization or other systemic reactions if sumatriptan-containing products are taken via other routes, e.g., orally or subcutaneously. It is possible that some patients who developed ACD with sumatriptan by exposure to ZECUITY, and who have developed systemic sensitization, may not be able to take sumatriptan in any form.</p>
<p>Patients who develop ACD with ZECUITY and require treatment with sumatriptan via other routes should receive their first subsequent dose under close medical supervision.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e2b3728e-fd27-4a77-a2f7-18fde92682ac"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal’s Angina </h2>
<p class="First">The use of ZECUITY is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, occurring within a few hours following administration of sumatriptan. Some of these reactions occurred in patients without known CAD. 5-HT<span class="Sub">1</span> agonists, including ZECUITY, may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (Prinzmetal’s angina), even in patients without a history of CAD.</p>
<p>Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of CAD) prior to using ZECUITY. Do not use ZECUITY if there is evidence of CAD or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> [<span class="Italics">see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</span>]. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider using the first ZECUITY TDS in a medically supervised setting and performing an electrocardiogram (ECG) upon activation of ZECUITY. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of ZECUITY.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4b25deb8-1d4e-4263-b2c8-59664056e7ec"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> </h2>
<p class="First">Life-threatening disturbances of cardiac rhythm, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported within a few hours following the administration of 5-HT<span class="Sub">1</span> agonists. Discontinue ZECUITY if these disturbances occur. ZECUITY is contraindicated in patients with Wolff-Parkinson-White syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders [<span class="Italics">see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3b651027-8f4b-495a-bd26-db1704acd1ab"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Chest, Throat, Neck and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure </h2>
<p class="First">Sensations of tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pressure, and heaviness in the chest, throat, neck, and jaw commonly occur after treatment with sumatriptan and are usually non-cardiac in origin. However, perform a cardiac evaluation if these patients are at high cardiac risk. The use of ZECUITY is contraindicated in patients shown with CAD and those with Prinzmetal’s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> [<span class="Italics">see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7b1a6b7b-1fd2-4da5-9379-a201fe0215d6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Cerebrovascular Events </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> have occurred in patients treated with 5-HT<span class="Sub">1</span> agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the 5-HT<span class="Sub">1</span> agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> when they were not. </p>
<p>As with other <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> therapies, before treating <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, exclude other potentially serious neurological conditions. ZECUITY is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA [<span class="Italics">see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e949668-c82d-48ca-b984-e4f0f34e2aaa"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions </h2>
<p class="First">5-HT<span class="Sub">1</span> agonists, including ZECUITY, may cause non-coronary vasospastic reactions, such as peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, gastrointestinal vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> (presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>), <span class="product-label-link" type="condition" conceptid="4044745" conceptname="Splenic infarction">splenic infarction</span>, and Raynaud’s syndrome. In patients who experience symptoms or signs suggestive of a vasospastic reaction following the use of any 5-HT<span class="Sub">1</span> agonist, rule out a vasospastic reaction before using ZECUITY [<span class="Italics">see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</span>].</p>
<p>Reports of transient and permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and significant partial <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> have been reported with the use of 5-HT<span class="Sub">1</span> agonists. Since visual disorders may be part of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack, a causal relationship between these events and the use of 5-HT<span class="Sub">1</span> agonists have not been clearly established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_82e22dcc-4358-4b6a-ba99-6258c4f2236f"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </h2>
<p class="First">Overuse of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs (e.g., ergotamine, triptans, opioids, combination of drugs for 10 or more days per month) may lead to exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> may present as <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-like daily <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or as a marked increase in frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>) may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bf802f75-3bba-4c36-ac33-b1c6fd356613"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may occur with triptans, including ZECUITY, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [<span class="Italics">see Drug Interactions (</span><span class="Italics"><a href="#ID_de8f4e6e-89dc-4d8f-a517-976b5ae1aa6d">7.4</a>)</span>]. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue ZECUITY if <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> is suspected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3083bf10-ba96-4e4d-ab4a-31badaa4f6c0"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Increase in Blood Pressure </h2>
<p class="First">Significant elevation in blood pressure, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT<span class="Sub">1</span> agonists, including patients without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor blood pressure in patients treated with ZECUITY. ZECUITY is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> [<span class="Italics">see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a12d6238-32d7-4aed-8f65-c4c4c66d5040"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> </h2>
<p class="First">Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving sumatriptan. Such reactions can be life threatening or fatal. In general, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. ZECUITY is contraindicated in patients with prior serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9678e9b7-85d8-4569-8065-c6834ec98175"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported following administration of sumatriptan. Some have occurred in patients with either a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or concurrent conditions predisposing to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. There are also reports in patients where no such predisposing factors are apparent. ZECUITY should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or conditions associated with a lowered <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d88c4f5e-9997-431f-a820-0f2a16cff191"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Electrically-active Implantable or Body-worn Medical Devices </h2>
<p class="First">ZECUITY should not be applied in areas near or over electrically-active implantable or body-worn medical devices (e.g., implantable cardiac pacemaker, body-worn insulin pump, implantable deep brain stimulator).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_d1f78207-5ffe-46b1-9269-7a97908f7831"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS </h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the prescribing information: </p>
<dl>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic Contact Dermatitis</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_aa49bd42-caf1-4480-97e8-4565044fa70a">5.2</a>)]</span>
</dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and Prinzmetal’s angina <span class="Italics">[see Warnings and Precautions (<a href="#ID_e2b3728e-fd27-4a77-a2f7-18fde92682ac">5.3</a>)]</span>
</dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_4b25deb8-1d4e-4263-b2c8-59664056e7ec">5.4</a>)] </span>
</dd>
<dt>·</dt>
<dd>Chest, throat, neck, and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>/tightness/pressure <span class="Italics">[see Warnings and Precautions (<a href="#ID_3b651027-8f4b-495a-bd26-db1704acd1ab">5.5</a>)] </span>
</dd>
<dt>·</dt>
<dd>Cerebrovascular events <span class="Italics">[see Warnings and Precautions (<a href="#ID_7b1a6b7b-1fd2-4da5-9379-a201fe0215d6">5.6</a>)] </span>
</dd>
<dt>·</dt>
<dd>Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> reactions <span class="Italics">[see Warnings and Precautions (<a href="#ID_6e949668-c82d-48ca-b984-e4f0f34e2aaa">5.7</a>)]</span>
</dd>
<dt>·</dt>
<dd>Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_82e22dcc-4358-4b6a-ba99-6258c4f2236f">5.8</a>)]</span>
</dd>
<dt>·</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span><span class="Italics"> [see Warnings and Precautions (<a href="#ID_bf802f75-3bba-4c36-ac33-b1c6fd356613">5.9</a>)]</span>
</dd>
<dt>·</dt>
<dd>Increase in blood pressure <span class="Italics">[see Warnings and Precautions (<a href="#ID_3083bf10-ba96-4e4d-ab4a-31badaa4f6c0">5.10</a>)] </span>
</dd>
<dt>·</dt>
<dd>Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_a12d6238-32d7-4aed-8f65-c4c4c66d5040">5.11</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2f4a8f8c-da04-485c-86b1-1f5e0d3fbb88"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>In two long-term, open-label studies in which patients were allowed to treat multiple <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks for up to 1 year, 15% (99 out of 662) withdrew from the study because of adverse reaction. The most common adverse reactions leading to withdrawal from the study were <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> (4%) and <span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">application site pain</span> (4%).</p>
<p>The most common adverse reactions (≥ 5%) in a controlled single dose study were <span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">application site pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, warmth, and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>.</p>
<p><span class="Bold"><span class="Italics">Controlled single dose <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> study</span></span></p>
<p><a href="#_Ref414536650">Table 1</a> lists adverse reactions that occurred at a frequency of 2% or greater in a controlled clinical study of ZECUITY in patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> (Study 1) [] In that study, patients randomized to the control group used the same activated iontophoretic transdermal delivery system (TDS) as patients randomized to ZECUITY, with the only difference being the absence of sumatriptan in the drug reservoir. Therefore, patients in the control group were exposed to same TDS-related risks as patients in the ZECUITY group, minus the risks related to sumatriptan. Only reactions that occurred at a frequency of 2% or more in patients treated with ZECUITY or control are included in <a href="#_Ref414536650">Table 1</a>.</p>
<a name="_Ref414536650"></a><table cellpadding="2.9pt" width="68.04%">
<caption><span>Table 1: Adverse Reactions Reported by at least 2% of Patients in Study 1</span></caption>
<col width="40%">
<col width="22%">
<col width="16%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"><span class="Bold">Adverse Reaction</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">Percent of Subjects Reporting</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">ZECUITY</span><br><span class="Bold">(n = 234)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Control</span><br><span class="Bold">(n = 235)</span>
</th>
</tr>
</thead>
<tbody><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">Application site pain</span></dd>
<dt> </dt>
<dd>Application site <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></dd>
<dt> </dt>
<dd>Application site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></dd>
<dt> </dt>
<dd>Application site warmth</dd>
<dt> </dt>
<dd>Application site <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4318383" conceptname="Application site irritation">Application site irritation</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4319312" conceptname="Application site pigmentation changes">Application site discoloration</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">26%</p>
<p>9%</p>
<p>8%</p>
<p>6%</p>
<p>6%</p>
<p>4%</p>
<p>3%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">17%</p>
<p>16%</p>
<p>7%</p>
<p>3%</p>
<p>6%</p>
<p>2%</p>
<p>1%</p>
</td>
</tr></tbody>
</table>
<p>The incidence of “atypical sensations? adverse events (<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, sensation warm/<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>) and “pain and other pressure sensations? (<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>/tightness/pressure/heaviness or neck/throat/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, tightness, pressure or heaviness) was 2% each in ZECUITY-treated patients, vs. 0% in the control group. Application site <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> was reported in 2 ZECUITY-treated patients (0.9%) vs. no patient in the control group. </p>
<p>Subgroup analyses of age (≤41 years, &gt;41 years), race (Caucasian, non-Caucasian) and body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) (≤25.7 mg/kg<span class="Sup">2</span>, &gt;25.7 mg/kg<span class="Sup">2</span>) showed no difference between subgroups for adverse events.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin Irritation</span> Examination</span></p>
<p>In Study 1, patients performed their own examination of the TDS application site at 4, 12, and 24 hours post TDS activation, and daily thereafter until resolution. <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin irritation</span> examination scores are summarized in <a href="#_Ref414536792"></a> The median time to “no redness? was 2.6 days for ZECUITY compared with 0.3 day in the control group.</p>
<a name="_Ref414536792"></a><table cellpadding="2.9pt" width="83.34%">
<caption><span>Table 2: Subject Self-examination <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin Irritation</span> Scoring</span></caption>
<col width="16%">
<col width="47%">
<col width="17%">
<col width="15%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Time-point</span></th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">ZECUITY</span><br><span class="Bold">(n = 234)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Control</span><br><span class="Bold">(n = 235)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>4 hours</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>No or minimal <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></dd>
<dt> </dt>
<dd>Moderate <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></dd>
<dt> </dt>
<dd>Intense <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> </dd>
<dt> </dt>
<dd>Intense <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>/broken skin</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">39%</p>
<p>55%</p>
<p>4%</p>
<p>2%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">73%</p>
<p>24%</p>
<p>1%</p>
<p>2%</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>12 hours</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>No or minimal <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></dd>
<dt> </dt>
<dd>Moderate <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></dd>
<dt> </dt>
<dd>Intense <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> </dd>
<dt> </dt>
<dd>Intense <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>/broken skin</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">69%</p>
<p>27%</p>
<p>2%</p>
<p>2%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">90%</p>
<p>9%</p>
<p>0%</p>
<p>1%</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>24 hours</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>No or minimal <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></dd>
<dt> </dt>
<dd>Moderate <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></dd>
<dt> </dt>
<dd>Intense <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> </dd>
<dt> </dt>
<dd>Intense <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>/broken skin</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">79%</p>
<p>19%</p>
<p>1%</p>
<p>1%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">93%</p>
<p>6%</p>
<p>0%</p>
<p>1%</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span> across clinical studies (Controlled single dose <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> study and long term safety studies)</span></span></p>
<p>In the controlled and uncontrolled clinical studies combined (n = 796 unique ZECUITY-treated subjects), the frequency of <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> of clinical interest is presented in <a href="#_Ref414536804">Table 3</a>.</p>
<a name="_Ref414536804"></a><table cellpadding="2.9pt" width="43.34%">
<caption><span>Table 3: <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reactions</span></span></caption>
<col width="25%">
<col width="24%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Event</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Percent of Subjects Reporting</span><br><span class="Bold"> (N = 796)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>Discoloration</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact Dermatitis</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>Irritation</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Vesicles</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>Erosion</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4%</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_88eecc54-b37a-48a5-9463-43ef33f3307f"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dd93d7f9-5ebe-4b41-81d0-6d2b3ae30e4d"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Ergot-Containing Drugs </h2>
<p class="First">Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and ZECUITY within 24 hours of each other is contraindicated <span class="Italics">[see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b61ea82b-1a2f-4a67-87fb-9a07434ccf0b"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Monoamine Oxidase-A Inhibitors </h2>
<p class="First">MAO-A inhibitors increase systemic exposure by 2-fold. Therefore, the use of ZECUITY in patients receiving MAO-A inhibitors is contraindicated <span class="Italics">[see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>) and Clinical Pharmacology (<a href="#ID_ed5b332d-61e9-4d8d-8656-3d3d2c7249eb">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1b3c04bf-e4b3-4689-939e-1a1a3572b918"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Other 5-HT<span class="Sub">1 </span>Agonists </h2>
<p class="First">Because their vasospastic effects may be additive, coadministration of ZECUITY and other 5-HT<span class="Sub">1</span> agonists (e.g., triptans) within 24 hours of each other is contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_de8f4e6e-89dc-4d8f-a517-976b5ae1aa6d"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported during coadministration of triptans and SSRIs or SNRIs, SNRIs, TCAs, and MAO inhibitors <span class="Italics">[see Warnings and Precautions (<a href="#ID_bf802f75-3bba-4c36-ac33-b1c6fd356613">5.9</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_80a3f332-42df-44ae-8be9-dcc6665472a2"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_f6e39cff-472e-4add-8f1d-18811e4b8c94"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy </h2>
<p class="First"><span class="Underline">Pregnancy Category C</span>: There are no adequate and well-controlled studies in pregnant women. ZECUITY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>When sumatriptan was administered intravenously to pregnant rabbits daily throughout the period of organogenesis, embryolethality was observed at doses at or close to those producing maternal toxicity. Oral administration of sumatriptan to rabbits during organogenesis was associated with increased incidences of fetal vascular and skeletal abnormalities; the highest no-effect dose for these effects was 15 mg/kg/day. The intravenous administration of sumatriptan to pregnant rats throughout organogenesis did not produce evidence of embryolethality. The subcutaneous administration of sumatriptan to pregnant rats prior to and throughout pregnancy did not produce evidence of embryolethality or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_7bec7cb2-61eb-49bc-a974-a22a917d8f97"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers </h2>
<p class="First">It is not known whether sumatriptan is excreted in human milk following transdermal administration. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from ZECUITY, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_b33a15f4-9a1a-4d3b-8295-5b1303d17806"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use </h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. </p>
<p>Two controlled clinical trials evaluated sumatriptan nasal spray (5 to 20 mg) in 1,248 adolescent migraineurs aged 12 to 17 years who treated a single attack. The trials did not establish the efficacy of sumatriptan nasal spray compared with placebo in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> in adolescents. Adverse reactions observed in these clinical trials were similar in nature to those reported in clinical trials in adults. </p>
<p>Five controlled clinical trials (2 single-attack studies, 3 multiple-attack studies) evaluating oral sumatriptan (25 to 100 mg) in pediatric patients aged 12 to 17 years enrolled a total of 701 adolescent migraineurs. These studies did not establish the efficacy of oral sumatriptan compared to placebo in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> in adolescents. Adverse events observed in these clinical trials were similar in nature to those reported in clinical trials in adults. The frequency of all adverse events in these patients appeared to be both dose- and age dependent, with younger patients reporting events more commonly than older adolescents. </p>
<p>Post-marketing experience documents that serious adverse events have occurred in the pediatric population after use of subcutaneous, oral, and/or intranasal sumatriptan. These reports include events similar in nature to those reported rarely in adults, including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, visual loss, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. A <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been reported in a 14-year-old male following the use of oral sumatriptan; clinical signs occurred within 1 day of drug administration. Since clinical data to determine the frequency of serious adverse reactions in pediatric patients who might receive subcutaneous, oral, or intranasal sumatriptan are not presently available, the use of ZECUITY in patients under 18 years of age is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_395fb0a8-a11f-4172-9030-51a7af4e5298"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use </h2>
<p class="First">Clinical trials of ZECUITY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. </p>
<p>A cardiovascular evaluation is recommended for geriatric patients who have other cardiovascular risk factors (e.g., <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of CAD) prior to using ZECUITY <span class="Italics">[see Warnings and Precautions (<a href="#ID_e2b3728e-fd27-4a77-a2f7-18fde92682ac">5.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_5cfb919a-b9fe-4c23-89c2-04c20baaa3f6"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE </h1>
<p class="First">No gross <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in clinical practice have been reported. <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">Coronary vasospasm</span> was observed after intravenous administration of sumatriptan injection <span class="Italics">[see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)]. </span><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> would be expected from animal data (dogs at 0.1 g/kg, rats at 2 g/kg) to possibly cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, inactivity, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of the extremities, reduced <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (<span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>, and <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scab</span> formation), and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>.</p>
<p>The apparent elimination half-life of sumatriptan after ZECUITY administration is about 3 hours <span class="Italics">[see Clinical Pharmacology <a href="#ID_ed5b332d-61e9-4d8d-8656-3d3d2c7249eb">12.3</a>)], </span>and therefore monitoring of patients after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with ZECUITY should continue for at least 15 hours or while symptoms or signs persist.</p>
<p>It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_fddbb5f8-78c2-42af-acd8-1ae4ca831cda"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION </h1>
<p class="First">ZECUITY (sumatriptan iontophoretic transdermal system) is a disposable, single use system designed to deliver sumatriptan through the skin using iontophoresis.  Iontophoresis is a non-invasive method of delivering a drug through the skin using a low electrical current. The ZECUITY electronics, powered by two coin cell lithium batteries, control the amount of current applied and the rate and amount of sumatriptan delivered.</p>
<p>Sumatriptan succinate, the active component of ZECUITY, is a selective 5-hydroxy-tryptamine receptor subtype 1 (5-HT<span class="Sub">1</span>) agonist (triptan). Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1), and has the following structure:</p>
<div class="Figure">
<a name="id-1951062346"></a><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-02.jpg">
</div>
<p>The empirical formula is C<span class="Sub">14</span>H<span class="Sub">21</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S•C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">4</span> representing a molecular weight of 413.5.  </p>
<p>Sumatriptan succinate is a white to off-white powder that is freely soluble in water. Each ZECUITY iontophoretic transdermal system contains 86 mg sumatriptan (base) as the succinate salt in an aqueous formulation. ZECUITY, upon activation, delivers 6.5 mg of sumatriptan through the skin over 4 hours <span class="Italics">[see Dosage and Administration (<a href="#ID_dccc3bcf-654a-43d5-a4b2-da37d120e369">2</a>)].</span></p>
<p>ZECUITY iontophoretic transdermal system is composed of an iontophoretic device and a drug reservoir card.  The reservoir card contains 2 non-woven pads and 2 different gel formulations; one a sumatriptan succinate formulation and the other a sodium salt formulation. The sumatriptan succinate formulation and pad contains the following inactive ingredients: purified water, basic butylated methacrylate copolymer (polyamine), lauric acid, adipic acid, methylparaben and a non-woven viscose pad. The salt formulation and pad contains: purified water, hydroxypropylcellulose, sodium chloride, methylparaben and a non-woven viscose pad.  ZECUITY is a non-sterile product.</p>
<p>The iontophoretic device consists of medical grade adhesive fabric and foam and a plastic dome that contains an activation button, batteries, and electronics (see <a href="#_Ref275193793">Figure 2</a>).</p>
<dl>
<dt> </dt>
<dd><span class="Bold">Figure <a href="#">2</a>:	Iontophoretic Device</span></dd>
</dl>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><p class="First"><span class="Bold">Top View</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Bottom View</span></p></td>
</tr>
<tr class="Botrule Last">
<td valign="top">
<a name="id-1951062342"></a><img alt="TopView" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-03.jpg">
</td>
<td valign="top">
<a name="id-1951062336"></a><img alt="BottomView" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-04.jpg">
</td>
</tr>
</tbody>
</table>
<p>The sumatriptan and salt pads are housed in individual reservoirs. Each reservoir is sealed by a foil strip that is removed prior to transfer of the pads to the iontophoretic device (see <a href="#_Ref275193815">Figure 3</a>). The iontophoretic device and foil reservoirs are co-packaged in a single unit pouch <span class="Italics">[see Patient Counseling Information (<a href="#ID_454aae2a-29f0-49a7-b7d7-63b264951e17">17</a>)].</span></p>
<dl>
<dt> </dt>
<dd><span class="Bold">Figure <a href="#">3</a>:	Reservoir Card </span></dd>
</dl>
<div class="Figure">
<a name="id-1951062328"></a><img alt="Figure3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-05.jpg">
</div>
<p>For ZECUITY to function, the pads must completely cover the electrodes <span class="Italics">[see Patient Counseling Information (<a href="#ID_454aae2a-29f0-49a7-b7d7-63b264951e17">17</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_2e7583b3-88f8-49eb-a1ae-55e3b59695b8"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_8a1494e1-61ac-4cf5-89d4-3457f505f99b"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action </h2>
<p class="First">Sumatriptan is the active component of ZECUITY. Sumatriptan binds with high affinity to human cloned 5-HT<span class="Sub">1B/1D </span>receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> by binding to 5-HT<span class="Sub">1B/1D</span> receptors located on intracranial blood vessels and sensory nerves of the trigeminal system. </p>
<p>Current theories proposed to explain the etiology of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> suggest that symptoms are due to local cranial <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> and/or to the release of sensory neuropeptides (including substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of sumatriptan for the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> is thought to be due to the agonist effects at the 5-HT<span class="Sub">1B/1D </span>receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_316eac2f-a722-4bde-b134-a4b97bcdb3a0"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics </h2>
<p class="First"><span class="Underline">Blood Pressure</span>: Significant elevation in blood pressure, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, has been reported in patients treated with sumatriptan, with and without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_3083bf10-ba96-4e4d-ab4a-31badaa4f6c0">5.10</a>)]</span>.</p>
<p><span class="Underline">Peripheral (Small) Arteries</span>: In healthy volunteers (N = 18), a trial evaluating the effects of sumatriptan on peripheral (small vessel) arterial reactivity failed to detect a clinically significant increase in peripheral resistance. </p>
<p><span class="Underline">Heart Rate</span>: Transient increases in blood pressure observed in some subjects in clinical trials carried out during sumatriptan’s development as a treatment for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> were not accompanied by any clinically significant changes in heart rate.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_ed5b332d-61e9-4d8d-8656-3d3d2c7249eb"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<p class="First"><span class="Underline">Absorption and Bioavailability</span>: Following ZECUITY administration to the upper arm the maximum mean sumatriptan serum concentration (C<span class="Sub">max</span>) was 22 ng/mL, the mean total area under the curve (AUC<span class="Sub">0-inf</span>) was 110 hr*ng/mL, and the median t<span class="Sub">max</span> was 1.1 hours. The mean C<span class="Sub">max</span> and mean AUC<span class="Sub">0-inf</span> measured after ZECUITY administration were approximately 37% and 45% of the values measured after administration of 100 mg Imitrex<span class="Sup">®</span> tablets, respectively.</p>
<p>The effect of ZECUITY application to the upper arm versus thigh was assessed in 19 healthy subjects. The application sites are considered interchangeable as the relative bioavailability of sumatriptan following application of the ZECUITY TDS to these two sites was comparable.  </p>
<p><span class="Underline">Distribution</span>: Protein binding, determined by equilibrium dialysis over the concentration range of 10 to 1000 ng/mL, is between 14% and 21%. The effect of sumatriptan on the protein binding of other drugs has not been evaluated. The apparent volume of distribution of sumatriptan is 2.4 L/kg. </p>
<p><span class="Underline">Metabolism</span>: <span class="Italics">In vitro </span>studies with human microsomes suggest that sumatriptan is metabolized by MAO, predominantly the A isoenzyme. No new metabolites were identified in comparison with the oral sumatriptan tablets. Most of a radiolabeled sumatriptan dose that is excreted in the urine is the major metabolite indole acetic acid (IAA) or the IAA glucuronide, both of which are inactive. </p>
<p><span class="Underline">Elimination</span>: After a single ZECUITY dose in 9 subjects, 11% of the sumatriptan dose was excreted in the urine as unchanged sumatriptan and 69% as the indole acetic acid metabolite. After a single ZECUITY dose, the mean sumatriptan half-life was 3.1 hours.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Effect</span>: Similar pharmacokinetic values were observed during a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack compared to a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-free period following ZECUITY administration on the upper arm in 18 patients with a diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</p>
<p><span class="Underline">External Heat Source</span>: A heat effect study in 12 healthy adult subjects demonstrated similar pharmacokinetic values without and with the application of an external heat source (40°C heat wrap placed over top of the ZECUITY TDS for the 4 hour dosing period).</p>
<p><span class="Underline">Special Populations:</span></p>
<p><span class="Italics">Age</span>: The pharmacokinetics of sumatriptan after ZECUITY administration to the upper arm were compared for 8 healthy elderly subjects versus 8 paired gender and race matched healthy young adult subjects. No significant pharmacokinetic differences were observed. <span class="Italics">[see Use In Specific Populations (<a href="#ID_395fb0a8-a11f-4172-9030-51a7af4e5298">8.5</a>)].</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of sumatriptan has not been examined. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>:<span class="Italics"></span>The effect of mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on the pharmacokinetics of subcutaneously administered sumatriptan has been evaluated. There were no significant differences in the pharmacokinetics of subcutaneously administered sumatriptan in moderately hepatically impaired subjects compared with healthy controls. The pharmacokinetics of subcutaneously administered sumatriptan in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been studied. The use of ZECUITY in this population is contraindicated <span class="Italics">[see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)]</span>.</p>
<p><span class="Italics">Race</span>: The effect of race on sumatriptan pharmacokinetics after ZECUITY administration was assessed in an analysis of 8 pooled Phase 1 studies with 168 healthy subjects (50 non-Caucasian and 118 Caucasian). C<span class="Sub">max</span> is about 8% lower and AUC<span class="Sub">0-4 </span>hours is about 10% lower in non-Caucasian compared to Caucasian subjects, respectively. These differences are not expected to be clinically significant.</p>
<p><span class="Italics">Gender</span>: No effect of gender on sumatriptan pharmacokinetics was identified in a study in 17 healthy subjects (8 male and 9 female).</p>
<p><span class="Underline">Drug Interaction Studies</span>:<span class="Italics"> Monoamine Oxidase-A Inhibitors: </span>In a study of 14 healthy females, pretreatment with an MAO-A inhibitor decreased the clearance of sumatriptan, resulting in a 2-fold increase in the area under the sumatriptan plasma concentration-time curve (AUC), corresponding to a 40% increase in elimination half-life. <span class="Italics">[see Contraindications (<a href="#ID_219c4583-242a-4bd2-b0d7-a6ec50ebc1e6">4</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_0c11ced2-4119-46ff-acdd-28a42c87af8b"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY </h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_c975d1b8-49fe-4e1c-bd6a-5ce177be1e5f"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<p class="First"><span class="Underline">Carcinogenesis</span>: In carcinogenicity studies, rats and mice were given sumatriptan by oral gavage. Mice were dosed for 78 weeks and rats were dosed for 104 weeks. There was no evidence of an increase in tumors in either species related to sumatriptan administration. </p>
<p><span class="Underline">Mutagenesis</span>: Sumatriptan was not mutagenic in the presence or absence of metabolic activation when tested in two gene mutation assays (the Ames test and the in vitro mammalian Chinese hamster V79/HGPRT assay). It was not clastogenic in two cytogenetics assays (in vitro human lymphocyte assay and in vivo rat micronucleus assay). </p>
<p><span class="Underline">Impairment of Fertility</span>: A fertility study by the subcutaneous route, during which male and female rats were dosed daily with sumatriptan prior to and throughout the mating period, demonstrated no evidence of impaired fertility. However, following oral administration, a treatment-related decrease in fertility, secondary to a decrease in mating, was seen for rats treated with 50 and 500 mg/kg/day. It is not clear whether the problem is associated with the treatment of males or females or both.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_66bd8bde-177c-4d18-ade7-f4aa027deb6b"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology </h2>
<p class="First"><span class="Underline">Corneal Opacities</span>: Dogs receiving oral sumatriptan developed corneal opacities and defects in the corneal epithelium. Corneal opacities were seen at the lowest dosage tested, 2 mg/kg/day, and were present after 1 month of treatment. Defects in the corneal epithelium were noted in a 60-week study. Earlier examinations for these toxicities were not conducted and no-effect doses were not established. </p>
<p><span class="Underline">Melanin Binding</span>: In rats with a single subcutaneous dose (0.5 mg/kg/day) of radiolabeled sumatriptan, the elimination half-life of radioactivity from the eye was 15 days, suggesting that sumatriptan and its metabolites bind to the melanin of the eye. The clinical significance of this binding is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_6760df48-4dee-447a-ab2a-74cd3538d12a"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a8014326-4b51-4371-8dba-50f089904257"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Acute Migraine</span> Attack – Placebo Controlled Efficacy Study </h2>
<p class="First">The efficacy of ZECUITY in the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> was demonstrated in a randomized, double-blind, controlled study (Study 1). </p>
<p>Patients in Study 1 were predominantly female (85%) and Caucasian (82%), with a mean age of 41 years. Patients were instructed to treat a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with a single ZECUITY TDS or matching TDS with no sumatriptan in the drug reservoir. Additional medications were allowed as rescue therapy beginning 2 hours after the initial treatment.</p>
<p>The primary efficacy endpoint in Study 1 was the proportion of patients who had no <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at 2 hours post TDS activation. Absence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> at 2 hours post TDS activation were assessed as secondary endpoints. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief, defined as a reduction in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-related <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> severity from moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, was also assessed. As shown in <a href="#_Ref414537196">Table 4</a>, a significantly greater proportion of patients had no <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, had <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief, no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, no <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span>, or no <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> at two hours after TDS activation in the ZECUITY treatment group than in the control group.</p>
<a name="_Ref414537196"></a><table width="100%">
<caption><span>Table 4: Percentage of Patients with No <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, With <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief, No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, No <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">Photophobia</span>, and No <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">Phonophobia</span> Two Hours After TDS Activation</span></caption>
<col width="30%">
<col width="22%">
<col width="25%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold">Two Hours After ZECUITY TDS Activation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold"><span class="Italics">p</span> value</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">ZECUITY<br>(n = 226)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo<br>(n = 228)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">No <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">18%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0092</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">With <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">53%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">29%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">&lt;0.0001</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">84%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">63%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">&lt;0.0001</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">No <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">Photophobia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">51%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">36%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0028</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">Phonophobia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">55%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">39%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0002</p></td>
</tr>
</tbody>
</table>
<p>Analyses of the relationship between age, race, gender, or BMI and response showed no significant differences in response rates.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_2bf29a4c-bdda-4e98-91ae-e122d652c309"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING </h1>
<p class="First">ZECUITY contains 86 mg sumatriptan that delivers 6.5 mg of sumatriptan over 4 hours.  </p>
<p>After use, fold used system so the adhesive side sticks to itself and safely discard away from children and pets. ZECUITY contains lithium-manganese dioxide batteries; dispose in accordance with state and local regulations.</p>
<p>Store at room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Do not store in the refrigerator or freezer.</p>
<p>ZECUITY is packaged individually in a sealed pouch. ZECUITY is supplied in cartons of 4 systems, NDC 51759-101-04.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_454aae2a-29f0-49a7-b7d7-63b264951e17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<p class="First">See FDA-approved patient labeling (Patient Information and Instructions for Use).</p>
<dl>
<dt> </dt>
<dd><span class="Bold">How to Use ZECUITY</span></dd>
</dl>
<p>Advise patients to carefully read the Patient Instructions for Use. Only patients who are able to understand and follow the instructions should use ZECUITY. </p>
<p>Advise patients that the ZECUITY iontophoretic transdermal system (TDS) must be properly applied and activated within 15 minutes of initiating Step 1 (Pull Tabs) of the Patient Instructions for Use, or the TDS will not operate.</p>
<p>Advise patients not to bathe, shower or swim while wearing ZECUITY.</p>
<p>Advise patients that upon removal of the ZECUITY TDS, most patients experience some skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> under the transdermal system, which usually disappears within 24 hours.</p>
<p>Advise patients that ZECUITY is single-use and should not be cut. Advise patients that no more than two ZECUITY TDS should be used in a 24 hour period, and that a second ZECUITY TDS should not be applied until at least 2 hours after activation of the first ZECUITY TDS <span class="Italics">[see Dosage and Administration (<a href="#ID_dccc3bcf-654a-43d5-a4b2-da37d120e369">2</a>)].</span></p>
<p>Instruct patients to apply the ZECUITY TDS to the upper arm or thigh and not to other areas of the body. Instruct patients to apply the ZECUITY TDS to dry intact, non-irritated skin on a site that is relatively hair free and without <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>, tattoos, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span>, or other skin conditions (i.e., generalized <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span> or disease including <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, melanoma, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>). </p>
<p>Advise patients that the ZECUITY TDS should not be applied to a previous application site until the site remains <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> free for 3 days <span class="Italics">[see Dosage and Administration (<a href="#ID_dccc3bcf-654a-43d5-a4b2-da37d120e369">2</a>)].</span></p>
<p>Inform patients that the safety of using more than 4 ZECUITY in one month has not been established.</p>
<dl>
<dt> </dt>
<dd><span class="Bold">Risk of Injury during Magnetic Resonance Imaging (MRI) procedure</span></dd>
</dl>
<p>Inform patients that ZECUITY contains metal parts and must be removed before an MRI procedure.</p>
<dl>
<dt> </dt>
<dd><span class="Bold">Potential for <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic Contact Dermatitis</span></span></dd>
</dl>
<p>Caution patients about the potential for developing <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> (ACD) after use of ZECUITY. Inform patients of the signs and symptoms of ACD, and instruct patients to seek medical advice if they develop <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span> suggestive of ACD. Inform patients that it is possible that some patients who develop ACD with sumatriptan by exposure to ZECUITY may not be able to take sumatriptan in any form.</p>
<p><span class="Bold">Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>, Prinzmetal’s Angina, Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-related Events, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, and Cerebrovascular Events</span></p>
<p>Inform patients that the medication in ZECUITY or other triptans may cause serious cardiovascular side effects such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious cardiovascular events can occur without warning symptoms, advise patients that they should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and should seek medical advice when observing any indicative sign or symptoms. Apprise patients of the importance of this follow-up<span class="Italics"> [see Warnings and Precautions (</span><span class="Italics"><a href="#ID_e2b3728e-fd27-4a77-a2f7-18fde92682ac">5.3</a>, <a href="#ID_4b25deb8-1d4e-4263-b2c8-59664056e7ec">5.4</a>, <a href="#ID_3b651027-8f4b-495a-bd26-db1704acd1ab">5.5</a>, and <a href="#ID_7b1a6b7b-1fd2-4da5-9379-a201fe0215d6">5.6</a>)].</span></p>
<p><span class="Bold">Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span></p>
<p>Inform patients that anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving sumatriptan. Such reactions can be life threatening or fatal. In general, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens <span class="Italics">[see Warnings and Precautions (<a href="#ID_a12d6238-32d7-4aed-8f65-c4c4c66d5040">5.11</a>)]</span>.</p>
<dl>
<dt> </dt>
<dd><span class="Bold">Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></dd>
</dl>
<p>Inform patients that use of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs for 10 or more days per month may lead to an exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and encourage patients to record <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> frequency and drug use (e.g., by keeping a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> diary) <span class="Italics">[see Warnings and Precautions (<a href="#ID_82e22dcc-4358-4b6a-ba99-6258c4f2236f">5.8</a>)].</span></p>
<dl>
<dt> </dt>
<dd><span class="Bold">Pregnancy</span></dd>
</dl>
<p>Inform patients that ZECUITY should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus <span class="Italics">[see Use in Specific Populations (<a href="#ID_f6e39cff-472e-4add-8f1d-18811e4b8c94">8.1</a>)].</span></p>
<dl>
<dt> </dt>
<dd><span class="Bold">Nursing Mothers</span></dd>
</dl>
<p>Advise patients to notify their physician if they are breast-feeding or plan to breast-feed <span class="Italics">[see Use in Specific Populations (<a href="#ID_7bec7cb2-61eb-49bc-a974-a22a917d8f97">8.3</a>)].</span></p>
<dl>
<dt> </dt>
<dd><span class="Bold">Ability To Perform Complex Tasks</span></dd>
</dl>
<p>Since <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> or treatment with sumatriptan may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, instruct patients to evaluate their ability to perform complex tasks during <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks and after using ZECUITY.</p>
<dl>
<dt> </dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span></dd>
</dl>
<p>Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of ZECUITY or other triptans, particularly during combined use with SSRIs, SNRIs, TCAs, and MAO inhibitors <span class="Italics">[see Warnings and Precautions (<a href="#ID_bf802f75-3bba-4c36-ac33-b1c6fd356613">5.9</a>) and Drug Interactions (<a href="#ID_de8f4e6e-89dc-4d8f-a517-976b5ae1aa6d">7.4</a>)].</span></p>
<p>Manufactured for NuPathe Inc. by LTS</p>
<p>Lohmann Therapie-Systeme AG, D-56626 </p>
<p>Andernach, Germany</p>
<p>and by LTS Lohmann Therapy Systems Corp., </p>
<p>West Caldwell, NJ 07006</p>
<p>NuPathe, Inc., is a wholly-owned subsidiary of Teva Pharmaceuticals USA, Inc.</p>
<p>©2014 Teva Pharmaceuticals USA, Inc.</p>
<p>All rights reserved.</p>
<p>ZEC-001</p>
<p>Teva logo</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="ID_b8a4458d-0513-4554-92f8-348d7a193db2"></a><a name="section-16"></a><p></p>
<h1>INSTRUCTIONS FOR USE </h1>
<dl>
<dt> </dt>
<dd>
<span class="Bold">ZECUITY<span class="Sup">® </span></span>(zeh-CUE-eh-tee)</dd>
</dl>
<p class="First">(sumatriptan iontophoretic transdermal system) </p>
<p>For topical use</p>
<p>Read this Patient Instructions for Use before using your ZECUITY and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">Your ZECUITY Transdermal System (TDS):</span><span class="Bold">See Figure A</span></p>
<p><span class="Bold">Figure A</span></p>
<div class="Figure">
<a name="id-912466288"></a><img alt="FigureA" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-06.jpg">
</div>
<p><span class="Bold">Preparation</span></p>
<p>ZECUITY is a single-use Transdermal System (TDS) or patch.</p>
<dl>
<dt>•</dt>
<dd>Remove ZECUITY by folding and tearing from the notch at the corner of the clear pouch<span class="Bold">.</span><span class="Bold">See </span>
</dd>
<dt>•</dt>
<dd>ZECUITY TDS should not be cut.</dd>
<dt>•</dt>
<dd>Do not use ZECUITY TDS if the clear pouch is torn or damaged.</dd>
</dl>
<p><span class="Bold">Figure B</span></p>
<div class="Figure">
<a name="id-912466287"></a><img alt="FigureB" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-07.jpg">
</div>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Choose an application site:</span><span class="Bold">See </span>
</dd>
</dl>
<p><span class="Bold">Figure C</span></p>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless"><tr class="First Last Toprule">
<td valign="top">
<a name="id-912466286"></a><img alt="FigureC" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-08.jpg">
</td>
<td valign="top">
<p class="First">Choose an application site on your upper arm or thigh. <span class="Bold">Do not</span> apply ZECUITY to any other body parts.</p>
<p>Choose an area of skin that is dry, clean and relatively hair free.</p>
<p><span class="Bold">Do not</span> apply ZECUITY over skin that is red or irritated. Skin should be free of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> and irritation for at least 3 days prior to application.</p>
<p><span class="Bold">Do not</span> apply ZECUITY over <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>, tattoos, scratches, <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span>, or broken skin.</p>
</td>
</tr></tbody>
</table>
<p><span class="Bold">The following steps will show you the right way to use ZECUITY</span></p>
<p><span class="Bold">Step 1</span> – <span class="Bold">Pull Tabs</span></p>
<p>To apply the ZECUITY TDS you must pull the 2 foil tabs.  These tabs are marked on the package as Step 1a and Step 1b. <span class="Bold">See </span></p>
<dl>
<dt>•</dt>
<dd>Place ZECUITY on a flat surface with the foil packets facing up.</dd>
<dt>•</dt>
<dd>While holding the package, pull both foil tabs out, 1 at a time, and throw the foil tabs away in the trash.  </dd>
</dl>
<p><span class="Bold">Note:</span> You must apply and activate ZECUITY within 15 minutes of completing Step 1.</p>
<p><span class="Bold">Figure D</span></p>
<div class="Figure">
<a name="id-912466285"></a><img alt="FigureD" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-09.jpg">
</div>
<p><span class="Bold">Step 2 </span>– <span class="Bold">Rub Foil Packets</span></p>
<p>ZECUITY has 2 foil packets that each contain a white medication pad that <span class="Bold">must</span> be properly attached to the ZECUITY TDS before use.</p>
<dl>
<dt>•</dt>
<dd>To transfer and attach the medication pads to the ZECUITY TDS use 2 fingers and firmly press and rub each foil packet, tracing the green arrow 3 times around.  <span class="Bold">See </span>
</dd>
</dl>
<p><span class="Bold">Figure E</span></p>
<div class="Figure">
<a name="id-912466284"></a><img alt="FigureE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-10.jpg">
</div>
<p><span class="Bold">Step 3</span><span class="Bold">– Unfold and Lift Open</span></p>
<p>Unfold the orange flap, marked as Step 3 on the bottom of the packet and lift open the package. <span class="Bold">See </span></p>
<p><span class="Bold">Figure F</span></p>
<div class="Figure">
<a name="id-912466283"></a><img alt="FigureF" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-11.jpg">
</div>
<p><span class="Bold">Step 4 - Peel Pads and Check</span></p>
<dl>
<dt>•</dt>
<dd>Slowly peel the first part of the ZECUITY TDS back from the silver liner.  If the medication pad is not attached, lay the ZECUITY TDS down on a hard surface and repeat Steps 2 and 3. <span class="Bold">See </span>
</dd>
</dl>
<p><span class="Bold">Figure G</span></p>
<div class="Figure">
<a name="id-912466282"></a><img alt="FigureG" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-12.jpg">
</div>
<p>After checking to make sure that both white medication pads are securely attached, peel the ZECUITY TDS completely away from liner. <span class="Bold">See </span></p>
<dl>
<dt>•</dt>
<dd>The ZECUITY TDS will not work properly if both medication pads are not attached.</dd>
<dt>•</dt>
<dd>There may be gel left in the reservoirs after the ZECUITY TDS is</dd>
<dt> </dt>
<dd>peeled back from the silver liner.</dd>
</dl>
<p><span class="Bold">Figure H</span></p>
<div class="Figure">
<a name="id-912466281"></a><img alt="FigureH" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-13.jpg">
</div>
<p><span class="Bold">Step 5 – Apply and Activate</span></p>
<p>Apply ZECUITY to your upper arm or thigh and activate it by pressing the button to turn it on. The button will blink and then turn solid red as it releases the medicine. </p>
<p><span class="Bold">See </span></p>
<dl>
<dt>•</dt>
<dd>If the light does not turn solid red or goes off within the first 15 minutes of application this means no medicine is being delivered. The TDS should be gently removed and thrown away. See “How to safely remove and throw away ZECUITY TDS? for instructions. You can immediately apply a new TDS to a different application site.  </dd>
<dt>•</dt>
<dd>Wear the TDS for 4 hours or until the red light goes off. </dd>
<dt>•</dt>
<dd>If the red light turns off before 4 hours, the TDS has stopped delivering your medicine and should be gently removed and thrown away. See “How to safely remove and throw away ZECUITY TDS? for instructions. If you still have <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, another ZECUITY TDS can be applied to a different application site. </dd>
</dl>
<p><span class="Bold">Figure I</span></p>
<div class="Figure">
<a name="id-912466280"></a><img alt="FigureI" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-14.jpg">
</div>
<p><span class="Bold">Important Information about using ZECUITY TDS:</span></p>
<dl>
<dt>•</dt>
<dd>You may feel slight <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or a mild <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> within 30 seconds of activating the ZECUITY TDS after pressing the button.</dd>
<dt>•</dt>
<dd>If ZECUITY begins to peel off, the ZECUITY TDS may be taped down with <span class="Bold">medical</span> tape. </dd>
<dt>•</dt>
<dd>You must keep ZECUITY dry. Do not bathe, shower, or swim while wearing ZECUITY.</dd>
<dt>•</dt>
<dd>Do not have a Magnetic Resonance Imaging (MRI) while wearing ZECUITY.</dd>
<dt>•</dt>
<dd>Remove ZECUITY if you have a painful <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> during use.</dd>
</dl>
<p><span class="Bold">How to safely remove and throw away ZECUITY TDS:</span></p>
<dl>
<dt>•</dt>
<dd>Slowly remove ZECUITY to minimize <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>. Gently clean the area with mild soap and water to remove any medicine that might be left on the skin.</dd>
<dt>•</dt>
<dd>ZECUITY TDS contains lithium-manganese dioxide batteries. Talk to your pharmacist or healthcare provider about how to follow state and local regulations when throwing away ZECUITY. </dd>
<dt>•</dt>
<dd>After use, fold your used ZECUITY TDS so the adhesive side sticks to itself and safely throw it away.</dd>
<dt>•</dt>
<dd>Keep ZECUITY out of the reach of children and pets. </dd>
</dl>
<p><span class="Bold">How should I store ZECUITY?</span></p>
<dl>
<dt>•</dt>
<dd>Store ZECUITY TDS at room temperature between 68°F to 77°F (20°C to 25°C).</dd>
<dt>•</dt>
<dd>Do not store ZECUITY in the refrigerator or freezer. </dd>
</dl>
<p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for NuPathe Inc. by LTS</p>
<p>Lohmann Therapie-Systeme AG, D-56626 </p>
<p>Andernach, Germany</p>
<p>and by LTS Lohmann Therapy Systems Corp., </p>
<p>West Caldwell, NJ 07006</p>
<p>NuPathe, Inc., is a wholly-owned subsidiary of Teva Pharmaceuticals USA, Inc.</p>
<p>©2014 Teva Pharmaceuticals USA, Inc.</p>
<p>All rights reserved.<br></p>
<p>ZECIFU-001</p>
<p>Revised: April 2014</p>
<p>Teva logo</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_b8749374-2ce7-46e7-89e4-55b78e664da2"></a><a name="section-17"></a><p></p>
<h1>PATIENT INFORMATION </h1>
<dl>
<dt> </dt>
<dd>
<span class="Bold">ZECUITY<span class="Sup">® </span></span>(zeh-CUE-eh-tee)</dd>
</dl>
<p class="First">(sumatriptan iontophoretic transdermal system) </p>
<p>for topical use</p>
<p>Read this Patient Information before you start using ZECUITY and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. </p>
<p><span class="Bold">What is the most important information I should know about ZECUITY?</span></p>
<p><span class="Bold">ZECUITY can cause serious side effects, including:</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> and other heart problems.  Heart problems may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  </span></p>
<p><span class="Bold">Stop using ZECUITY and get emergency medical help right away if you have any of the following symptoms of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>:  </span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in the center of your chest that lasts for more than a few minutes, or that goes away and comes back </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> that feels like an uncomfortable heavy pressure, squeezing, fullness, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in your arms, back, neck, jaw, or stomach </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> with or without <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span></dd>
<dt>•</dt>
<dd>breaking out in a <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>•</dt>
<dd>feeling lightheaded<br>
</dd>
</dl>
<p>ZECUITY is not for people with risk factors for heart disease unless a heart exam is done and shows no problem. You have a higher risk for heart disease if you: </p>
<dl>
<dt>•</dt>
<dd>have high blood pressure </dd>
<dt>•</dt>
<dd>have high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels </dd>
<dt>•</dt>
<dd>smoke </dd>
<dt>•</dt>
<dd>are overweight </dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> </dd>
<dt>•</dt>
<dd>have a family history of heart disease</dd>
<dt>•</dt>
<dd>are a female who has gone through <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span></dd>
<dt>•</dt>
<dd>are a male over age 40</dd>
</dl>
<p><span class="Bold"><br>What is ZECUITY?</span></p>
<p>ZECUITY is a prescription medicine used for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults. ZECUITY comes in an iontophoretic transdermal system (TDS) that uses a mild electrical current to deliver the medicine sumatriptan through your skin. </p>
<p>ZECUITY is used for people who have been told by a healthcare provider that they have <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>. </p>
<p>ZECUITY is not used to prevent or decrease the number of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> you have.  </p>
<p>It is not known if ZECUITY is safe and effective in children under 18 years of age.</p>
<p><span class="Bold">Who should not use ZECUITY?</span></p>
<p><span class="Bold">Do not use ZECUITY if you have: </span></p>
<dl>
<dt>•</dt>
<dd>heart problems or a history of heart problems </dd>
<dt>•</dt>
<dd>had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span> (TIAs), or problems with your blood circulation</dd>
<dt>•</dt>
<dd>narrowing of blood vessels to your legs, arms, stomach, or kidney (<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>)</dd>
<dt>•</dt>
<dd>uncontrolled high blood pressure</dd>
<dt>•</dt>
<dd>hemiplegic <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. If you are not sure if you have these types of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>, ask your healthcare provider </dd>
<dt>•</dt>
<dd>taken any of the following medicines in the last 24 hours:<dl>
<dt>o</dt>
<dd>almotriptan (AXERT<span class="Sup">®</span>)</dd>
<dt>o</dt>
<dd>eletriptan (RELPAX<span class="Sup">®</span>) </dd>
<dt>o</dt>
<dd>frovatriptan (FROVA<span class="Sup">®</span>) </dd>
<dt>o</dt>
<dd>naratriptan (AMERGE<span class="Sup">®</span>) </dd>
<dt>o</dt>
<dd>rizatriptan (MAXALT<span class="Sup">®</span>, MAXALT-MLT<span class="Sup">®</span>) </dd>
<dt>o</dt>
<dd>sumatriptan and naproxen (TREXIMET<span class="Sup">®</span>) </dd>
<dt>o</dt>
<dd>ergotamines (CAFERGOT<span class="Sup">®</span>, ERGOMAR<span class="Sup">®</span>, MIGERGOT<span class="Sup">®</span>)</dd>
<dt>o</dt>
<dd>dihydroergotamine (D.H.E. 45<span class="Sup">®</span>, MIGRANAL<span class="Sup">®</span>)</dd>
</dl>
</dd>
<dt> </dt>
<dd>Ask your healthcare provider if you are not sure if your medicine is listed above.</dd>
<dt>•</dt>
<dd>severe liver problems</dd>
<dt>•</dt>
<dd>an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to sumatriptan, the medicine in ZECUITY, or any of the components in ZECUITY TDS. See the end of this leaflet for a complete list of ingredients in ZECUITY.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before using ZECUITY? </span></p>
<p>Before you use ZECUITY, tell your healthcare provider about all of your medical conditions, including if you: </p>
<dl>
<dt>•</dt>
<dd>have high blood pressure </dd>
<dt>•</dt>
<dd>have high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> </dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> </dd>
<dt>•</dt>
<dd>smoke </dd>
<dt>•</dt>
<dd>are overweight </dd>
<dt>•</dt>
<dd>are a female who has gone through <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span></dd>
<dt>•</dt>
<dd>have heart problems or family history of heart problems or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> </dd>
<dt>•</dt>
<dd>have liver problems </dd>
<dt>•</dt>
<dd>have had <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> </dd>
<dt>•</dt>
<dd>are not using effective birth control </dd>
<dt>•</dt>
<dd>have or have had any side effects caused by the use of electrical devices. Talk to your healthcare provider if you are not sure if you have a medical electronic device or sensitivities to electrical devices.  </dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if ZECUITY will harm your unborn baby. </dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if the medicine in ZECUITY passes into your breast milk.  You and your healthcare provider should decide if you will use ZECUITY or breastfeed. You should not do both.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and nonprescription medicines, vitamins, and herbal supplements. </p>
<p>Using ZECUITY with certain other medicines can affect each other, causing serious side effects.</p>
<p><span class="Bold">Especially tell your healthcare provider if </span>you take anti-depressant medicines called: </p>
<dl>
<dt>•</dt>
<dd>selective serotonin reuptake inhibitors (SSRIs) </dd>
<dt>•</dt>
<dd>serotonin norepinephrine reuptake inhibitors (SNRIs) </dd>
<dt>•</dt>
<dd>tricyclic antidepressants (TCAs) </dd>
<dt>•</dt>
<dd>monoamine oxidase inhibitors (MAOIs) </dd>
</dl>
<p><br>Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. </p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I use ZECUITY? </span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Read the Instructions for Use in the package that comes with your ZECUITY TDS for information about the right way to use ZECUITY TDS.</span></dd>
<dt>•</dt>
<dd>Certain people should apply their first dose of ZECUITY in their healthcare provider’s office or in another medical setting. Ask your healthcare provider if you should use your first dose in a medical setting. </dd>
<dt>•</dt>
<dd>ZECUITY is for use on the skin only. </dd>
<dt>•</dt>
<dd>Use ZECUITY exactly as your healthcare provider tells you to.</dd>
<dt>•</dt>
<dd>Apply 1 ZECUITY to your upper arm or thigh. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Do not</span> apply ZECUITY to other areas of your body. Talk to your healthcare provider if you are not sure where to apply ZECUITY.</dd>
<dt>•</dt>
<dd>If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> comes back or you only get some relief from your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, you may apply a second ZECUITY to your other arm or thigh, no sooner than 2 hours after the activation of the previously applied ZECUITY.  </dd>
<dt>•</dt>
<dd>Do not apply more than 2 ZECUITY in 24 hours.</dd>
<dt> </dt>
<dd>•	If you use too much ZECUITY, call your healthcare provider or go to the nearest hospital emergency room right away.</dd>
<dt>•</dt>
<dd>It is not known if using more than 4 ZECUITY in 1 month is safe.</dd>
</dl>
<p><span class="Bold">What should I avoid while using ZECUITY?</span></p>
<p>•	Do not bathe, shower, or swim while wearing ZECUITY.</p>
<dl>
<dt> </dt>
<dd>•	ZECUITY can cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. If you have these symptoms, do not drive a car, use machinery, or do anything where you need to be alert. </dd>
<dt>•</dt>
<dd>You should remove ZECUITY before you have a Magnetic Resonance Imaging (MRI) procedure.</dd>
</dl>
<p><span class="Bold"><br>What are the possible side effects of ZECUITY?</span></p>
<p>See “What is the most important information I should know about ZECUITY??</p>
<p><span class="Bold">ZECUITY may cause serious side effects including:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">injury during a Magnetic Resonance Imaging (MRI). </span> The ZECUITY TDS contains metal parts and must be removed before an MRI.</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> (ACD). </span>Some people have had a serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> called <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> (ACD) where ZECUITY is applied. Symptoms of ACD include:<dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or irritation of skin</dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of your skin</dd>
<dt>o</dt>
<dd>warmth or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> of skin</dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> that ooze, drain, or crust over</dd>
</dl>
</dd>
<dt> </dt>
<dd>You should stop using ZECUITY and call your healthcare provider if you have any of the symptoms of ACD.  If you have or have had ACD while using ZECUITY and need to take sumatriptan by mouth or injection, your first dose of sumatriptan should be given in your healthcare provider’s office or in another medical setting.<br>
</dd>
<dt>•</dt>
<dd><span class="Bold">changes in color or sensation in your fingers and toes (Raynaud’s syndrome)</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">stomach and intestinal problems (gastrointestinal and colonic ischemic events).</span> Symptoms of gastrointestinal and colonic ischemic events include: <dl>
<dt>o</dt>
<dd>sudden or severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> after meals </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">problems with blood circulation to your legs and feet (peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>).</span> Symptoms of peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> include: <dl>
<dt>o</dt>
<dd>cramping and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your legs or hips </dd>
<dt>o</dt>
<dd>feeling of heaviness or tightness in your leg muscles </dd>
<dt>o</dt>
<dd>burning or aching <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your feet or toes while resting </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in your legs </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> feeling or color changes in 1 or both legs or feet </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>.</span> Some people who use too many ZECUITY may have worse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> get worse, your healthcare provider may decide to stop your treatment with sumatriptan.</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</span> <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> is a rare but serious problem that can happen in people using ZECUITY, especially if ZECUITY is used with anti-depressant medicines called SSRIs or SNRIs. </dd>
</dl>
<p>Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. </p>
<p>Call your healthcare provider right away if you have any of the following symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>: </p>
<dl>
<dt> </dt>
<dd><dl>
<dt>o</dt>
<dd>mental changes such as seeing things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>), <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> </dd>
<dt>o</dt>
<dd>fast heartbeat </dd>
<dt>o</dt>
<dd>changes in blood pressure </dd>
<dt>o</dt>
<dd>high body temperature</dd>
<dt>o</dt>
<dd>tight muscles </dd>
<dt>o</dt>
<dd>trouble walking </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
</dl></dd>
<dt>•</dt>
<dd>
<span class="Bold">increases in blood pressure. </span>You should not use ZECUITY if you have uncontrolled high blood pressure.</dd>
<dt>•</dt>
<dd>
<span class="Bold">serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>Get medical help right away if you have any of these symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:<span class="Italics"></span>
</dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, mouth, or tongue</dd>
<dt>o</dt>
<dd>trouble breathing</dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span></dd>
<dt>o</dt>
<dd>severe <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></dd>
<dt>o</dt>
<dd>fast heartbeat or pounding in your chest (<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>)</dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have happened in people taking sumatriptan who have never had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> before. Talk with your healthcare provider about your chance of having <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> while you take ZECUITY. </dd>
</dl>
<p><span class="Bold">The most common side effects of ZECUITY include</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, warmth, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> or a change in the skin color at the application site of ZECUITY.</p>
<p>Most people have some skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> after removal of ZECUITY. This <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> will usually go away in 24 hours. </p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of ZECUITY. For more information, ask your healthcare provider or pharmacist. </p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store ZECUITY? </span></p>
<dl>
<dt>•</dt>
<dd>Store ZECUITY at room temperature between 68°F to 77°F (20°C to 25°C). </dd>
<dt>•</dt>
<dd>Do not store ZECUITY in the refrigerator or freezer. </dd>
</dl>
<p><span class="Bold">Keep ZECUITY and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of ZECUITY</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZECUITY for a condition for which it was not prescribed. Do not give ZECUITY to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This Patient Information leaflet summarizes the most important information about ZECUITY. If you would like more information, talk to your healthcare provider. You can ask your healthcare provider or pharmacist for information about ZECUITY that is written for healthcare professionals. </p>
<p>For more information, go to www.ZECUITY.com or call 1-855-ZECUITY. </p>
<p><span class="Bold">What are the ingredients in ZECUITY?</span></p>
<p><span class="Bold">Active ingredient:</span>  sumatriptan succinate</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Sumatriptan Reservoir Card and pad:</span> purified water, basic butylated methacrylate copolymer (polyamine), lauric acid, adipic acid, methylparaben, and non-woven viscose pad. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Salt Reservoir Card and pad:</span>  purified water, hydroxypropylcellulose, sodium chloride, methylparaben, and non-woven viscose pad.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Iontophoretic device:</span> medical grade adhesive fabric, foam and plastic dome containing an activation button, coin cell lithium batteries, and electronics.</dd>
</dl>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>ZECUITY<span class="Bold"><span class="Sup">®</span></span> is a registered trademark of NuPathe Inc. The other brands listed are trademarks of their respective owners and are not trademarks of NuPathe. The makers of these brands are not affiliated with and do not endorse NuPathe or its products.</p>
<p>Manufactured for NuPathe Inc. by LTS</p>
<p>Lohmann Therapie-Systeme AG, D-56626 </p>
<p>Andernach, Germany</p>
<p>and by LTS Lohmann Therapy Systems Corp., </p>
<p>West Caldwell, NJ 07006<br></p>
<p>NuPathe, Inc., is a wholly-owned subsidiary of Teva Pharmaceuticals USA, Inc.</p>
<p>©2014 Teva Pharmaceuticals USA, Inc.</p>
<p>All rights reserved.</p>
<p>ZECPL-001</p>
<p>Revised:  April 2014</p>
<p>Teva logo</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_18ab40b9-3046-41bc-8a2c-ac748a30a2a7"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel, Part 1 of 2 </h1>
<div class="Figure">
<a name="id-1089218998"></a><img alt="Zecuity® (sumatriptan iontophoretic transdermal system) 6.5 mg/4 hours, 4s Carton, Part 1 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-15.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_cdf10412-ff28-408d-826e-e332e5d87661"></a><a name="section-19"></a><p></p>
<h1>Package/Label Display Panel, Part 2 of 2 </h1>
<div class="Figure">
<a name="id-1089218990"></a><img alt="Zecuity® (sumatriptan iontophoretic transdermal system) 6.5 mg/4 hours, 4s Carton, Part 2 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806a07a0-e042-11df-9548-0002a5d5c51b&amp;name=image-16.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_33c97ab3-297e-426d-8bbb-63987b38268e"></a><a name="section-19.1"></a><p></p>
<h2>Zecuity® (sumatriptan iontophoretic transdermal system) 6.5 mg/4 hours, 4s Carton Text </h2>
<p class="First"><span class="Bold">4 Transdermal Systems</span></p>
<p><span class="Bold">NDC 51759-101-04</span></p>
<p>Rx Only Dispose of Transdermal System Out of Reach of Children and Pets</p>
<p><span class="Bold">zecuity®</span></p>
<p><span class="Bold">(sumatriptan iontophoretic</span></p>
<p><span class="Bold">transdermal system)</span></p>
<p><span class="Bold">6.5 mg / 4 hours</span></p>
<p><span class="Bold">For Transdermal Use only</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZECUITY 		
					</strong><br><span class="contentTableReg">sumatriptan patch, extended release, electrically controlled</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51759-101</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TRANSDERMAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SUMATRIPTAN SUCCINATE</strong> (SUMATRIPTAN) </td>
<td class="formItem">SUMATRIPTAN</td>
<td class="formItem">6.5 mg  in 4 h</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LAURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ADIPIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51759-101-04</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem">08/25/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51759-101-01</td>
<td class="formItem">4 h in 1 PATCH; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202278</td>
<td class="formItem">08/25/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>NuPathe Inc.
							(601161495)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Teva Pharmaceuticals USA Inc (001627975)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9f74e5ee-95a1-4680-a81a-bcc30e71dc08</div>
<div>Set id: 806a07a0-e042-11df-9548-0002a5d5c51b</div>
<div>Version: 8</div>
<div>Effective Time: 20150825</div>
</div>
</div> <div class="DistributorName">NuPathe Inc.</div></p>
</body></html>
